secwatch / observer
8-K filed June 15, 2023, 7:59 PM ET ticker CMPX CIK 0001738021
other material confidence high sentiment neutral materiality 0.15

Compass Therapeutics announces results of 2023 annual meeting of stockholders

Compass Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Compass Therapeutics, Inc. shareholders approved Election of Class III Directors at the 2023-06-15 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-06-15
Exact text from the filing
Proposal No. 1. Election of Directors. The stockholders elected the two Class III nominees for director to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, by the votes set forth in the table below: Broker Non- Name For Withheld votes Thomas J Schuetz MD PHD 67,240,784 17,368,756 12,119,981 Richard S Lindahl MBA 84,596,658 12,882 12,119,981
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Compass Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-15 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-06-15
Exact text from the filing
Proposal No. 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of CohnReznick, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, by the votes set forth in the table below: Broker Non- For Against Abstained votes 96,574,239 130,740 24,542 0
View on SEC.gov

Browse all shareholder votes →

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001171843-23-003943
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.